Inatherys

Inatherys is a Paris-based, private biotech focused on developing monoclonal antibodies for high-need oncology and inflammatory diseases. Its lead programs, INA02 and INA03, are in preclinical development, targeting CD89 and CD71 receptors, respectively, to address conditions with limited therapeutic options. The company leverages strong academic roots from INSERM and Necker Hospital, with a management team combining deep scientific expertise and pharmaceutical industry experience. Inatherys operates as a pre-revenue, preclinical-stage company seeking to advance its candidates into clinical trials.

Development of monoclonal antibodies targeting specific cell surface receptors (CD71, CD89) involved in cancer proliferation and inflammatory pathways.

In oncology, CD71 is a relatively underexplored target, but Inatherys competes in the broad space of targeted therapies for refractory cancers. In inflammation, targeting CD89 is novel, but it enters a crowded field of biologics for asthma and arthritis, requiring clear differentiation from anti-cytokine and other pathway inhibitors.